31 Jan 2017
Wrap up interview: Cre8™ - How innovative technology enhances PCI clinical outcome
Is there a real difference in DES today, especially when it comes to answering the unmet needs involved in the treatment of the diabetic patient? Can an innovative polymer-free DES with a unique AmphilimusTM formulation provide a higher level of safety and efficacy? Join R. Mohd Ali, Kuala Lumpur, Malaysia along with J. Tan, Singapore and P. Stella, The Netherlands as they discuss the latest data and positive results of the polymer-free DES Cre8TM – an emerging tool in the armamentarium of the interventional cardiologist.
At the crossroads of BRS development: food for thought
31 Jan 2017
It is clear that we have reached a crossroads with the new technology which we call the "fully bioresorbable scaffold". Today, the community is somewhat insecure about the future of this new technology which is currently still in its early iterations.
What to expect in interventional cardiology in 2017
PCR Chair William Wijns gives us his take on 2017: expanded indications for TAVI, new BRS data, trials on device based therapies in arterial hypertension, launch of Stent Save a Life, slow implementation of interventional treatment of acute ischemic stroke, celebrating 40 years of balloon angioplasty and EuroPCR 2017. An exciting year lies ahead!
What determines long-term outcomes using fully bioresorbable scaffolds - the device, the operator or the lesion?
Consult the latest EuroIntervention article on Bioresorbable scaffolds by K. Yamaji, L. Räber, and S. Windecker
Efficacy and safety of dual antiplatelet therapy after complex PCI
10 Jan 2017
Practical tips and tricks for coronary intervention
20 Jan 2017 – From AsiaPCR/SingLIVE 2017
Bioresorbable scaffold (BRS)
19 Jan 2017
Consult this session on Bioresorbable scaffold (BRS), that includes a LIVE demonstration from the National Heart Insititute - Kuala Lumpur.
MASTER: Safety and efficacy of biodegradable polymer DES in management of patients with acute STEMI
From EuroPCR 2016
M. Valdes introduces the MASTER study showing us just how BMS were put to the test. Taking a close look at the treatment of patients with acute STEMI, MASTER compares DES with bioresorbable polymer with bare metal stents. And the outcomes? At 4 and 6 months, in a population representative of daily practice, the results were in favour of the DES.Learn more about the details of this study – efficacy and favourable short-term safety, late lost, target vessel failure.
BRS in long lesions - Optimising implantations results
By beginning with the question of what in fact constitutes a long lesion, M. Haude and N.E.J. West lead us through an illuminating discussion of bioresorbable scaffolds and why, with increasing experience they pose a valid alternative to the former dependence on a “full metal jacket” philosophy.What are the procedural aspects that differ with BRS that are essential in their good deployment? What are the specific pitfalls or structural concerns about these devices when used in long lesions? And what about DAPT? Learn more on where we stand today with the clinical uses of BRS…
BRS: experience, unresolved issues and the outlook for the next-generation
One of the hottest topics in stenting, bioresorbable scaffolds have captured the imagination of today’s interventionalists…but what is the status of these promising devices: their current data, challenges or future?Join M. Haude, A. Abizaid and N. E. J. West as they look at the efficacy and safety of first-generation BRS. What are their limitations and what lessons can we learn from available data and experience? Learn more as they touch on such subjects as the challenges of patient selection, lesion preparation and the use of imaging. Where are we going with BRS? Learn more here…